Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.
Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CF, Eng C, Neuhausen SL, Karlan B, Kim-Sing C, Huzarski T, Gronwald J, McCuaig J, Senter L, Tung N, Ghadirian P, Eisen A, Gilchrist D, Blum JL, Zakalik D, Pal T, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group. Kotsopoulos J, et al. Among authors: neuhausen sl. Breast Cancer Res Treat. 2014 Feb;143(3):579-86. doi: 10.1007/s10549-013-2823-4. Epub 2014 Jan 24. Breast Cancer Res Treat. 2014. PMID: 24458845
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, et al. Ford D, et al. Am J Hum Genet. 1998 Mar;62(3):676-89. doi: 10.1086/301749. Am J Hum Genet. 1998. PMID: 9497246 Free PMC article.
Cancer risks in BRCA2 mutation carriers.
Breast Cancer Linkage Consortium. Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999 Aug 4;91(15):1310-6. doi: 10.1093/jnci/91.15.1310. J Natl Cancer Inst. 1999. PMID: 10433620
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.
Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, Weber BL. Rebbeck TR, et al. Among authors: neuhausen sl. J Natl Cancer Inst. 1999 Sep 1;91(17):1475-9. doi: 10.1093/jnci/91.17.1475. J Natl Cancer Inst. 1999. PMID: 10469748
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch H; Hereditary Breast Cancer Clinical Study Group. Narod SA, et al. Among authors: neuhausen sl. Lancet. 2000 Dec 2;356(9245):1876-81. doi: 10.1016/s0140-6736(00)03258-x. Lancet. 2000. PMID: 11130383
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL; Prevention and Observation of Surgical End Points Study Group. Rebbeck TR, et al. Among authors: neuhausen sl. N Engl J Med. 2002 May 23;346(21):1616-22. doi: 10.1056/NEJMoa012158. Epub 2002 May 20. N Engl J Med. 2002. PMID: 12023993 Free article.
446 results